The Patent Finder

RaQualia Pharma Inc.

27 patents currently held · Updated Nov 16, 2026
11 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

4
Ending by 2030
Dec 2026
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Apr 30, 2027
    The maintenance fee for Fused Cyclic Urea Derivatives as CRHR2 Antagonist (US 11,802,120) comes due Apr 30, 2027. Unpaid by Nov 1, 2027, it lapses early.
  • 2 fees due May 17, 2027
  • 1 fee due Oct 5, 2027
    The maintenance fee for Arylamide derivatives as TTX-S blockers (US 9,302,991) comes due Oct 5, 2027. Unpaid by Apr 5, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,723,321Chromane substituted benzimidazole derivatives
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,252,790Pyrazole-3-carboxamide derivative having 5-HT2B receptor antagonist activity
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,697,877Oxyindole derivatives with motilin receptor agonistic activity
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,648,080Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,975,070Ghrelin receptor agonist for treatment of cachexia
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,187,463Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,137,1135-HT4 receptor agonist as a prokinetic agent
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,302,991Arylamide derivatives as TTX-S blockers
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,187,475Pyrrolopyridinone derivatives as TTX-S blockers
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,701,658Amide derivatives as TTX-S blockers
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 27 patents shown.
Pro members see all 27.
Pro members: see all 27 patents
Also on record, not counted in the 27: 11 patents in force now held by others · 17 lapsed for an unpaid fee · 22 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 abandoned · 5 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited